Portal de Periódicos da CAPES

Toxic epidermal necrolysis and co‐existent SARS‐CoV‐2 (COVID‐19) treated with intravenous immunoglobulin: ‘ Killing 2 birds with one stone ’

2020; Wiley; Volume: 35; Issue: 2 Linguagem: Inglês

10.1111/jdv.16887

1468-3083

M. Saha, A. D’Cruz, Navreet Paul, R. Healy, Damian Collins, Denis Charles, S. Sahu, A. Fonia,

Advancements in Transdermal Drug Delivery

Journal of the European Academy of Dermatology and VenereologyVolume 35, Issue 2 p. e97-e98 Letter to the Editor Toxic epidermal necrolysis and co-existent SARS-CoV-2 (COVID-19) treated with intravenous immunoglobulin: 'Killing 2 birds with one stone' M. Saha, M. Saha Queen Elizabeth Hospital, Lewisham and Greenwich NHS Trust, London, UKSearch for more papers by this authorA. D'Cruz, A. D'Cruz Queen Elizabeth Hospital, Lewisham and Greenwich NHS Trust, London, UKSearch for more papers by this authorN. Paul, N. Paul Queen Elizabeth Hospital, Lewisham and Greenwich NHS Trust, London, UKSearch for more papers by this authorR. Healy, R. Healy Queen Elizabeth Hospital, Lewisham and Greenwich NHS Trust, London, UKSearch for more papers by this authorD. Collins, D. Collins Queen Elizabeth Hospital, Lewisham and Greenwich NHS Trust, London, UKSearch for more papers by this authorD.-A. Charles, D.-A. Charles Queen Elizabeth Hospital, Lewisham and Greenwich NHS Trust, London, UKSearch for more papers by this authorS. Sahu, S. Sahu Queen Elizabeth Hospital, Lewisham and Greenwich NHS Trust, London, UKSearch for more papers by this authorA. Fonia, Corresponding Author A. Fonia [email protected] orcid.org/0000-0003-0040-6636 Queen Elizabeth Hospital, Lewisham and Greenwich NHS Trust, London, UK Correspondence: A. Fonia. E-mail: [email protected]Search for more papers by this author M. Saha, M. Saha Queen Elizabeth Hospital, Lewisham and Greenwich NHS Trust, London, UKSearch for more papers by this authorA. D'Cruz, A. D'Cruz Queen Elizabeth Hospital, Lewisham and Greenwich NHS Trust, London, UKSearch for more papers by this authorN. Paul, N. Paul Queen Elizabeth Hospital, Lewisham and Greenwich NHS Trust, London, UKSearch for more papers by this authorR. Healy, R. Healy Queen Elizabeth Hospital, Lewisham and Greenwich NHS Trust, London, UKSearch for more papers by this authorD. Collins, D. Collins Queen Elizabeth Hospital, Lewisham and Greenwich NHS Trust, London, UKSearch for more papers by this authorD.-A. Charles, D.-A. Charles Queen Elizabeth Hospital, Lewisham and Greenwich NHS Trust, London, UKSearch for more papers by this authorS. Sahu, S. Sahu Queen Elizabeth Hospital, Lewisham and Greenwich NHS Trust, London, UKSearch for more papers by this authorA. Fonia, Corresponding Author A. Fonia [email protected] orcid.org/0000-0003-0040-6636 Queen Elizabeth Hospital, Lewisham and Greenwich NHS Trust, London, UK Correspondence: A. Fonia. E-mail: [email protected]Search for more papers by this author First published: 17 August 2020 https://doi.org/10.1111/jdv.16887Citations: 9Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Creamer D, Walsh Sa, Dziewulski P et al. UK guidelines for the management of Stevens–Johnson syndrome/toxic epidermal necrolysis in adults 2016. J Plast Reconstr Aesthet Surg 2016; 69(6): e119–e153. 10.1016/j.bjps.2016.01.034 CASPubMedWeb of Science®Google Scholar 2Galván Casas C, Català A, Carretero Hernández G et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol 2020; 183(1): 71–77. https://doi.org/10.1111/bjd.19163 10.1111/bjd.19163 CASPubMedWeb of Science®Google Scholar 3Prete M, Favoino E, Catacchio G, Racanelli V, Perosa F. SARS-CoV-2 infection complicated by inflammatory syndrome. Could high-dose human immunoglobulin for intravenous use (IVIG) be beneficial? Autoimmun Rev 2020; 19: 102559. 10.1016/j.autrev.2020.102559 CASPubMedWeb of Science®Google Scholar 4Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `Cytokine Storm' in COVID-19. J Infect 2020; 80: 607–613. 10.1016/j.jinf.2020.03.037 CASPubMedWeb of Science®Google Scholar 5Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect 2020; 9: 727–732. 10.1080/22221751.2020.1746199 CASPubMedWeb of Science®Google Scholar 6Xie Y, Cao S, Dong H et al. Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19. J Infect 2020; 81: 318–356. 10.1016/j.jinf.2020.03.044 CASPubMedWeb of Science®Google Scholar 7Cao W, Liu X, Bai T et al.High-dose intravenous immunoglobulin as therapeutic option for deteriorating patients with coronavirus disease 2019. Open Forum Infect Dis 2020; 7: ofaa102. 10.1093/ofid/ofaa102 CASPubMedWeb of Science®Google Scholar 8Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-18 pandemic. Lancet 2020; 395(10237): 1607–1608. 10.1016/S0140-6736(20)31094-1 CASPubMedWeb of Science®Google Scholar Citing Literature Volume35, Issue2February 2021Pages e97-e98 ReferencesRelatedInformation